Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurixnews2025-04-02T14:40:03+00:00April 2nd, 2025|Endpoints News|
Prazer Therapeutics raises $20M; Carisma lets go of most staffnews2025-04-01T14:19:29+00:00April 1st, 2025|Endpoints News|
LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drugnews2025-03-31T14:57:15+00:00March 31st, 2025|Endpoints News|
DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in Chinanews2025-03-28T14:01:27+00:00March 28th, 2025|Endpoints News|
Nkarta to lay off 34% of staff; Savara’s debt financing dealnews2025-03-27T14:26:21+00:00March 27th, 2025|Endpoints News|
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancernews2025-03-26T14:10:15+00:00March 26th, 2025|Endpoints News|
Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kakennews2025-03-25T14:19:35+00:00March 25th, 2025|Endpoints News|
Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fundnews2025-03-24T14:57:42+00:00March 24th, 2025|Endpoints News|
Genfit’s up to €185M royalty deal; J&J’s Tremfya gets a Crohn’s approvalnews2025-03-21T15:28:10+00:00March 21st, 2025|Endpoints News|
Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI fundingnews2025-03-20T15:10:58+00:00March 20th, 2025|Endpoints News|
